Loncar China BioPharma ETF (CHNA) Launches on Nasdaq

Today, the Loncar China BioPharma ETF (Nasdaq: CHNA) begins trading on the Nasdaq in the United States. The CHNA ETF seeks to give investors access to China’s rapidly-developing biopharmaceutical industry. It is based on the Loncar China BioPharma Index, an innovative index developed by biotechnology investor Brad Loncar. It invests in 28 companies, 22 of which are listed on the Hong Kong Stock Exchange and six of which are listed on Nasdaq, offering investors distinct, global exposure through the convenience of one security.